APHON’s mission is to support and advance nurses and their practice in order to optimize outcomes for children, adolescents, and young adults with cancer and blood disorders and their families.
To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer.
Family Reach is a national 501(c)(3) nonprofit dedicated to removing the financial barriers standing between cancer patients and their treatment — such as loss of income, increased out-of-pocket expenses, and socioeconomic factors. When faced with these financial barriers, families have to make impossible decisions like choosing between paying for treatment or basic essentials like housing, food, and transportation. No family should have to choose between their health and their home — and we won
The Focused Ultrasound Foundation was created to improve the lives of millions of people worldwide by accelerating the development of focused ultrasound, an early-stage noninvasive therapeutic technology with the potential to transform the treatment of many medical disorders. Since its establishment in 2006, it has become the largest non-governmental source of funding for focused ultrasound research.
Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
We encourage, empower, and educate those living with Li-Fraumeni Syndrome by connecting them with care, resources, and others who are Living LFS.
Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. We base our approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Some people develop cancers that are caused by a single inappropriate DNA change, known as “oncogenic drivers.” When a genetic test identifies a patient with an oncogenic driver, there should be a personalized medicine to address this error in the DNA that is leading to the cancer. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.
Making Cancer Fun is the go-to resource for families facing childhood cancer. It offers practical ideas, tools and tips for parents interwoven with a personal story of resiliency and hope. Additionally, each chapter contains interactive workbook pages for parents, designed to meet the individual needs of their child. Get ready for a new cancer conversation!
National Brain Tumor Society (NBTS) unrelentingly invests in, mobilizes and unites our community to discover a cure, deliver effective treatments, and advocate for patients and care partners.
Oncoheroes is a groundbreaking biotech company 100% focused on discovering, developing, and commercializing new therapies for children and adolescents with cancer. We intend to become the global leader in delivering new pediatric oncology drugs.
At Sanofi, we chase the miracles of science to improve people’s lives.
We enable students to thrive academically and personally because our empathetic understanding of learners’ challenges, allows us to offer students holistic and innovative, solutions, that are personalized for students’ unique learning needs, developed to restore students’ confidence, and constructed to provide students with the tools they will need to overcome obstacles and achieve continued success.
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
The company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.